Company news

Natera, Inc. news in 2025

Natera, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 21, 2025

Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

December 17, 2025

I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer

December 15, 2025

Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer

December 11, 2025

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

December 9, 2025

Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting

December 8, 2025

Natera Acquires Foresight Diagnostics

December 4, 2025

New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

December 2, 2025

Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium

December 1, 2025

Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month

November 18, 2025

Natera Integrates with Flatiron Health’s OncoEMR® Platform

November 11, 2025

Natera Reports Third Quarter 2025 Financial Results

November 5, 2025

Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT

October 30, 2025

Natera to Report its Third Quarter Results on November 6, 2025

October 29, 2025

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

October 27, 2025

Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients

October 20, 2025

Natera Named to Fast Company’s Next Big Things in Tech List

October 15, 2025

Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings

October 12, 2025

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium

October 11, 2025

Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT

September 30, 2025

Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer

September 29, 2025

Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows

September 28, 2025

Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

August 29, 2025

Natera Provides Update on Patent Litigation with NeoGenomics

August 28, 2025

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

August 27, 2025

Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer

August 24, 2025

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

August 21, 2025

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

August 21, 2025

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

August 17, 2025

Natera Reports Second Quarter 2025 Financial Results

August 6, 2025

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

August 6, 2025

Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations

July 31, 2025

Natera to Report Its Second Quarter Results on August 7, 2025

July 30, 2025

Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

July 29, 2025

PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT

July 23, 2025

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

July 6, 2025

Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

June 30, 2025

Natera Announces Medicare Coverage for Signatera™ Genome

June 3, 2025

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

June 1, 2025

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

May 21, 2025

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

May 7, 2025

Natera Reports First Quarter 2025 Financial Results

May 7, 2025

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

May 6, 2025

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

May 4, 2025

Natera to Report its First Quarter Results on May 8, 2025

April 30, 2025

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

April 28, 2025

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

April 23, 2025

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

April 21, 2025

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

March 24, 2025

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

March 9, 2025

Older news releases →

Calls in 2025

Decks in 2025